 Shares of Redhill Biopharma Ltd. RDHL, -4.59 gained 7.0 in premarket trading on Monday after the company said it had new data from a Phase 23 clinical study evaluating its experimental oral antiviral opaganib in severely ill, hospitalized COVID-19 patients. 